Press Releases

MYOS RENS Technology Launches 30-Day Qurr® Fortetropin® Challenge

Download PDF

Award Winning Trainer Scott Keppel to Administer Challenge on the Vimify Mobile App

Initiative to Promote Qurr® as a Vital Component of a Regular Workout Regimen Geared to Quickly Put People Back on Track for Their Long-Term Fitness Goals

CEDAR KNOLLS, N.J., Jan. 16, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the natural food product that helps build lean muscle in conjunction with resistance training, today launched the Qurr® Fortetropin® Challenge (the "Challenge"), a new initiative that combines Fortetropin®-based Qurr® products with a workout and support plan designed by an award-winning and nationally certified personal trainer, Scott Keppel.


Joseph Mannello, Chief Executive Officer of MYOS, commented, "This is another initiative that reflects our commitment toward more aggressive product awareness and acceptance.  MYOS is eager to build partnerships with leading personal trainers and fitness centers, with a view towards reaching this key demographic."

The Challenge provides the perfect platform for people to get back on track for their long-term fitness goals. It combines a 30-day supply of Qurr® branded shakes containing Fortetropin®, which is clinically shown to help build lean muscle mass as part of a strength training program, with a 30-day workout program designed by Scott Keppel, to help shape muscles, increase strength, and burn significant fat. The workout regimen is designed to promote healthy eating, exercising, consistently using Qurr® and practicing healthy habits for these 30 days, so that the regimen will become part of the user's lifestyle and mindset.

Throughout the Challenge, users will log in to their Vimify account (a social health and fitness app) to receive clear and actionable lessons and habits, along with coaching and support from Scott Keppel. Users can invite friends, family or co-workers to monitor their progress and provide encouragement. Users gain permanent access to the content after the Challenge is complete.

"I am pleased to be partnering with Scott Keppel and his amazing team at Scott's Training Systems," continued Mr. Mannello. "Scott is well-known in the world of competition for his accomplishments in coaching bikini, figure, fitness, and body building contestants. Importantly, Scott shares our commitment to empowering individuals to create a healthy lifestyle and to meet their fitness and/or competitive goals."

For more information and to join the Qurr® Fortetropin® Challenge, please visit:  

About MYOS RENS Technology Inc. 
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™," is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, which has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. Fortetropin® is a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. MYOS believes Fortetropin® has the potential to redefine existing standards of physical health and wellness. For more information, please visit

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including Qurr® products, the success of our research and development, including our clinical studies, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to continue increasing our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations: 
Porter LeVay & Rose 
Michael Porter, President
Phone: 212-564-4700


Cision View original content with multimedia: